Company

Abbisko Cayman Ltd

Headquarters: Shanghai, China

Employees: 144

CEO: Dr. Yao-Chang Xu

HKEX: 2256 -2.75%

Detailed Description

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Abbisko Cayman Ltd has the following listings and related stock indices.


Stock: HKEX: 2256 wb_incandescent

Details

Headquarters:

Building 3, No. 898

Halei Road Zhangjiang Hi-Tech Park Pudong New Area

Shanghai, 201203

China

Phone: 86 21 6891 2098